Tradestie Institutional Equity Comparison Engine · Market Close Jan 30, 2026

MPW vs MNMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MPW Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

MPW Overall Winner 6-Pillar Tally: MPW 6 – 0 MNMD Matrix Metrics: MPW 7 – 3 MNMD

As of Jan 30, 2026, Medical Properties Trust, Inc. (MPW) is the stronger overall head-to-head candidate over Mind Medicine (MindMed) Inc. Common Shares (MNMD) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MPW carries a Unified Composite Score of 52.6/100 (HOLD) at $5.02 (6.7x Forward P/E, 58.2% operating margin), whereas MNMD carries 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MNMD currently prints a higher short-term Unified Composite Score (63.1/100 BUY vs. MPW 52.6/100 HOLD), MPW captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (58.2% vs. 0.0% operating margin) and revenue trajectory (+9.9% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MPW vs MNMD
MPW NYSE Head-to-Head Winner
Medical Properties Trust, Inc.
Real Estate Investment Trusts
$5.02
-0.59% 1D
Market Cap $3.0B
TTM Revenue $1.01B
Forward P/E 6.7x
Beta / 30D Vol 0.14β · 26% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 25.0 Fund 45.0 Flow 67.0 Mom 47.3
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.4 · SMA20: $5.18 · SMA50: $5.24
MNMD NASDAQ
Mind Medicine (MindMed) Inc. Common Shares
Medicinal Chemicals & Botanical Products
$15.02
+1.01% 1D
Market Cap $1.4B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.79β · 55% Vol
Unified Composite Score
63.1 / 100 BUY
Tech 75.0 Fund 62.0 Flow 60.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 65
RSI-14: 65.3 · SMA20: $13.52 · SMA50: $12.57

6-Pillar Scorecard Institutional Category Breakdown (MPW 6 – 0 MNMD)

Columns: Metric · MPW · MNMD
1. Valuation Multiples MPW
Forward P/E 6.7x N/M
Trailing P/E 6.7x N/M
PEG Ratio 1.93x N/M
EV / Revenue 3.0x N/M
2. Growth & Scale MPW
Revenue Growth (YoY) +9.9% +0.0%
Earnings Growth (YoY) -48.6% +0.0%
TTM Revenue (USD) $1.01B N/A
Market Cap $3.0B $1.4B
3. Profitability & Quality MPW
Gross Margin 96.4% N/A
Operating Margin 58.2% 0.0%
Net Profit Margin -70.1% 0.0%
Return on Equity (ROE) -14.0% -85.6%
4. Balance Sheet & Cash Flow MPW
Cash Generation (TTM) $823M EBITDA N/A
Cash Flow Margin 81.6% EBITDA Mgn N/A
Net Cash / Leverage $7.75 Book/Sh · -14.0% ROE $1.70 Book/Sh · -85.6% ROE
Dividend Yield 6.34% None (0.00%)
5. Options & Positioning MPW
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 24.3% (25th %ile) 70.7% (6th %ile)
Put/Call OI Skew 0.79x (Call-Skewed) 0.18x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat MPW
OpEx & R&D Intensity 38.2% of Rev ($385M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role REIT - Healthcare Facilities Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MPW (7) vs MNMD (3)
Institutional Metric MPW MNMD Criterion Row Edge
Market Capitalization
Scale
$3.0B $1.4B Larger Scale MPW
Trailing P/E Ratio
Valuation
6.7x N/M Lower Multiple MPW
Forward P/E Ratio
Valuation
6.7x N/M Lower Multiple MPW
Revenue Growth (YoY)
Growth
+9.9% +0.0% Higher Growth MPW
Operating Margin (TTM)
Profitability
58.2% 0.0% Higher Margin MPW
Net Profit Margin
Profitability
-70.1% 0.0% Higher Margin MNMD
Return on Equity (ROE)
Capital Efficiency
-14.0% -85.6% Higher ROE MPW
52-Week Range Position
Momentum
45% ($4–$6) 98% ($5–$15) Stronger Trend MNMD
Beta / 30D Volatility
Risk Regime
0.14β · 26% Vol 1.79β · 55% Vol Lower Realized Risk MPW
Unified Institutional Score
Composite Signal
52.6 / 100 (HOLD) 63.1 / 100 (BUY) Higher Composite MNMD
Trailing 12M Revenue (USD)
Operating Scale
$1.01B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
96.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.93x PEG · 3.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$823M EBITDA ($7.75 Book/Sh · -14.0% ROE) N/A ($1.70 Book/Sh · -85.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MNMD +18.95 pp
MPW: +0.59% · MNMD: +19.54%
3M Horizon MNMD +20.55 pp
MPW: -1.53% · MNMD: +19.02%
6M Horizon MNMD +49.69 pp
MPW: +25.37% · MNMD: +75.06%
1Y Horizon MNMD +88.37 pp
MPW: +16.82% · MNMD: +105.19%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MPW vs MNMD. Trailing 12-month operating profitability (MPW 58.2% vs MNMD 0.0%) and valuation multiples (MPW 6.7x vs MNMD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MPW ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.01B
Gross Margin96.4%
Op. Margin58.2%
ROE / Fwd P/E-14.0% · 6.7x
MNMD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MPW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.3%
IV Percentile 25th %ile
Put/Call OI Skew 0.79x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MPW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MNMD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 70.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MNMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MPW Moat Profile High-Margin Pricing Power Moat
REIT - Healthcare Facilities Operator
Competes within the REIT - Healthcare Facilities value chain with $3.0B market capitalization and 58.2% operating margin.
OpEx & R&D Reinvestment 38.2% of Rev ($385M)
90D Engineering Disclosures 0 Published
MNMD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MPW vs MNMD Key Questions & Quantitative Answers

As of Jan 30, 2026, Medical Properties Trust, Inc. (MPW) is the stronger overall head-to-head candidate over Mind Medicine (MindMed) Inc. Common Shares (MNMD) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MPW carries a Unified Composite Score of 52.6/100 (HOLD) at $5.02 (6.7x Forward P/E, 58.2% operating margin), whereas MNMD carries 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MNMD currently prints a higher short-term Unified Composite Score (63.1/100 BUY vs. MPW 52.6/100 HOLD), MPW captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (58.2% vs. 0.0% operating margin) and revenue trajectory (+9.9% vs. +0.0% YoY).

MPW leads the Growth & Scale pillar: MPW posts +9.9% YoY revenue growth and -48.6% YoY earnings growth on $1.01B TTM revenue (96.4% gross margin, 58.2% operating margin), compared with MNMD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MPW generates $1.01B in USD-normalized revenue versus N/A for MNMD. In operating R&D and SG&A reinvestment, MPW deploys 38.2% of Rev ($385M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNMD.

MPW screens cheaper on headline valuation multiples. MPW trades at 6.7x Forward P/E, 6.7x Trailing P/E, 1.93x PEG, and 3.0x EV/Revenue (81.6% EBITDA margin), whereas MNMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MPW (-14.0% ROE) versus MNMD (-85.6% ROE) capital efficiency.

In options market volatility and institutional positioning, MPW carries 24.3% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.79x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 26% Vol realized risk). By comparison, MNMD carries 70.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.79β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Jan 30, 2026. For educational research only; not investment advice.